![]() ![]() For these reasons, vaccinations are paramount for improving lung cancer survival outcomes during the pandemic. Populations particularly susceptible to COVID-19-related complications include lung cancer patients with active smoking history, chronic obstructive pulmonary disease, asthma, and/or interstitial lung disease. While the majority of infected patients (> 80%) only experience mild symptoms, some patients become hypoxic and require intensive-level care and mechanical ventilation to sustain oxygen requirements. Clinical presentation can range from asymptomatic or mild symptoms (for example, flu-like illness, malaise, anosmia, ageusia) to severe symptomatology with acute respiratory distress syndrome, intravascular coagulopathy, and/or multiorgan failure resulting in death. Now known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or by its related disease nomenclature of coronavirus disease 2019 (COVID-19), this strain primarily infects the respiratory tract, causing a myriad of symptoms. This case report highlights the importance of lymph node biopsies in lung cancer patients who present with contralateral lymphadenopathy following coronavirus disease 2019 vaccination to rule out tumor recurrence in this deserving patient population.Ī new strain of coronavirus was first detected in Wuhan, China, during the winter of 2019. Biopsy was pursued owing to concerns of treatment failure and confirmed recurrent malignancy. At the time, she had been receiving long-term immunotherapy for the treatment of advanced lung adenocarcinoma. Here, we present a case of a 61-year-old Caucasian female and former smoker who developed cervical, hilar, supraclavicular, mediastinal, and left retroauricular lymphadenopathy following her coronavirus disease 2019 booster vaccination. ![]() Reactive lymphadenopathy following the administration of a coronavirus disease 2019 vaccination can confound the radiographic interpretation of positron emission tomography–computed tomography or computed tomography scans from lung cancer patients receiving immunotherapy. ![]() In recent years, immunotherapy has taken a preeminent role in the treatment of non-small cell lung cancer with dramatic improvement in overall survival. As a high-risk population group, these patients are strongly advised to receive coronavirus disease 2019 vaccination in accordance with Center for Disease Control and Prevention guidelines to minimize morbidity and mortality. Given the current climate of the pandemic, lung cancer patients are especially vulnerable to complications from severe acute respiratory syndrome coronavirus 2 infection. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |